{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:48:47Z","timestamp":1770137327715,"version":"3.49.0"},"reference-count":58,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015841","name":"Nordic Nanovector ASA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015841","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005416","name":"Norwegian Research Council","doi-asserted-by":"crossref","award":["290685"],"award-info":[{"award-number":["290685"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: CD37, an antigen highly expressed in B-cell malignancies, served as the target in the LYMRIT-37-01 Part B (PARADIGME) and Part C studies employing a single intravenous injection of the radioimmunoconjugate 177Lu\u2013lilotomab satetraxetan (Betalutin\u00ae). Methods: Patients with follicular lymphoma (FL), grades I\u2013IIIa, who had received at least two previous lines of therapy and were refractory to at least one previous regimen with rituximab or an anti-CD20 agent, were included. They were randomized to receive either a 40 mg lilotomab pretreatment and an activity dosage of 15 MBq\/kg Betalutin (\u201c40\/15\u201d regimen) or 100 mg\/m2 of lilotomab and 20 MBq\/kg of Betalutin (\u201c100\/20\u201d regimen). In total, 109 patients were enrolled and received Betalutin, 72 of whom received the 40\/15 regimen and 28 received the 100\/20 regimen. An additional heavily pretreated \u201cspecial population\u201d of nine patients received 40\/12.5 (i.e., a reduced Betalutin dosage) due to low platelets and\/or a previous autologous stem cell transplant. Part C was a small expansion cohort of four patients, all receiving the 40\/15 regimen, and was designed to obtain supplementary pharmacokinetic data. Results: The efficacy analysis set comprised a total of 100 patients from the PARADIGME study. The overall response rates were 38.9% and 32.1%, and the complete response rates were 20.8% and 14.3% in the 40\/15 and 100\/20 groups, respectively. Correspondingly, the median response durations were 8.5 months and 3.4 months in the two groups. Hence, increasing the Betalutin activity dose by using the stronger protective CD37 pre-dosing (\u201c100\/20\u201d) did not improve the therapeutic benefit. The most common grade \u2265 3 adverse events were hematologic, including neutropenia (11.5%) and thrombocytopenia (8.0%), with nadirs occurring around weeks 5\u20137 and recovery by week 11. Conclusions: A single-dose administration of Betalutin had a mild toxicity profile with a clinically relevant response rate. It represents a viable treatment alternative in FL patients who are not suitable for more toxic and long-lasting treatments. Trial Registration: This trial was registered at clinicaltrials.gov under #NCT 01796171.<\/jats:p>","DOI":"10.3390\/ph19020250","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:00:47Z","timestamp":1770033647000},"page":"250","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase II Study of 177Lu\u2013Lilotomab Satetraxetan, a CD37 Antibody\u2013Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients"],"prefix":"10.3390","volume":"19","author":[{"given":"Roy H.","family":"Larsen","sequence":"first","affiliation":[{"name":"NucliThera AS, 0884 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[{"name":"Innlandet Hospital, 2819 Gj\u00f8vik, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Foss\u00e5","sequence":"additional","affiliation":[{"name":"Norwegian Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Repetto-Llamazares","sequence":"additional","affiliation":[{"name":"NucliThera AS, 0884 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6647-686X","authenticated-orcid":false,"given":"Knut T.","family":"Smerud","sequence":"additional","affiliation":[{"name":"Smerud Medical Research International AS, 0274 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3191-7324","authenticated-orcid":false,"given":"Timothy","family":"Illidge","sequence":"additional","affiliation":[{"name":"Christie NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester M20 4BX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7985-9919","authenticated-orcid":false,"given":"\u00d8yvind S.","family":"Bruland","sequence":"additional","affiliation":[{"name":"NucliThera AS, 0884 Oslo, Norway"},{"name":"Norwegian Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway"},{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0372 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) in the United States and Western Europe: Population-Level Projections for 2020\u20132025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_2","unstructured":"(2025, September 17). Surveillance, Epidemiology, and End Results Program, Available online: https:\/\/seer.cancer.gov\/index.html."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Thandra, K.C., Barsouk, A., Saginala, K., Padala, S.A., Barsouk, A., and Rawla, P. (2021). Epidemiology of Non-Hodgkin\u2019s Lymphoma. Med. Sci., 9.","DOI":"10.3390\/medsci9010005"},{"key":"ref_4","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in Observed and Relative Survival in Follicular Grade 1-2 Lymphoma during 4 Decades: The Stanford University Experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","article-title":"Burden of Lymphoma in China, 2006-2016: An Analysis of the Global Burden of Disease Study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/2040620717738740","article-title":"The Evolving Role of Targeted Biological Agents in the Management of Indolent B-Cell Lymphomas","volume":"8","author":"Wang","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular Lymphoma in the Modern Era: Survival, Treatment Outcomes, and Identification of High-Risk Subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bjh.15708","article-title":"Response Duration and Survival Shorten after Each Relapse in Patients with Follicular Lymphoma Treated in the Rituximab Era","volume":"184","author":"Magnano","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-21-5","article-title":"Genetic Heterogeneity in Follicular Lymphoma","volume":"5","author":"Perrett","year":"2021","journal-title":"Ann. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.16872","article-title":"The Investigation and Management of Follicular Lymphoma","volume":"191","author":"McNamara","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly Diagnosed and Relapsed Follicular Lymphoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1236","DOI":"10.1634\/theoncologist.2019-0138","article-title":"Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs","volume":"24","author":"Matasar","year":"2019","journal-title":"Oncologist"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized Trial of Bendamustine-Rituximab or R-CHOP\/R-CVP in First-Line Treatment of Indolent NHL or MCL: The BRIGHT Study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular Lymphoma: 2023 Update on Diagnosis and Management","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/hematology.2020000156","article-title":"How Do I Sequence Therapy for Follicular Lymphoma?","volume":"2020","author":"Salles","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early Event Status Informs Subsequent Outcome in Newly Diagnosed Follicular Lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","article-title":"How I Treat Early-Relapsing Follicular Lymphoma","volume":"133","author":"Casulo","year":"2019","journal-title":"Blood"},{"key":"ref_20","first-page":"97","article-title":"Follicular Lymphoma: A Focus on Current and Emerging Therapies","volume":"36","author":"Cahill","year":"2022","journal-title":"Oncology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","article-title":"Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Receiving Three or More Lines of Systemic Therapy (LEO CReWE): A Multicentre Cohort Study","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.15149","article-title":"Second-Line and Subsequent Therapy and Outcomes for Follicular Lymphoma in the United States: Data from the Observational National LymphoCare Study","volume":"184","author":"Link","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3324\/haematol.2021.278717","article-title":"Prospects in the Management of Patients with Follicular Lymphoma beyond First-Line Therapy","volume":"107","author":"Qualls","year":"2022","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrclinonc.2011.160","article-title":"Clinical Radioimmunotherapy\u2014The Role of Radiobiology","volume":"8","author":"Pouget","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.beha.2011.03.005","article-title":"Radioimmunotherapy in Follicular Lymphoma","volume":"24","author":"Illidge","year":"2011","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support","volume":"329","author":"Press","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_27","first-page":"3263","article-title":"Advantage of Lutetium-177 Versus Radioiodine Immunoconjugate in Targeted Radionuclide Therapy of b-Cell Tumors","volume":"34","author":"Abbas","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_28","first-page":"85","article-title":"Evaluating Antigen Targeting and Anti-Tumor Activity of a New Anti-CD37 Radioimmunoconjugate Against Non-Hodgkin\u2019s Lymphoma","volume":"33","author":"Dahle","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1182\/bloodadvances.2020002583","article-title":"Phase 1\/2a Study of 177Lu-Lilotomab Satetraxetan in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma","volume":"4","author":"Kolstad","year":"2020","journal-title":"Blood Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/sj.leu.2403822","article-title":"Aberrant Expression of Tetraspanin Molecules in B-Cell Chronic Lymphoproliferative Disorders and Its Correlation with Normal B-Cell Maturation","volume":"19","author":"Barrena","year":"2005","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","article-title":"Targeting CD37-Positive Lymphoid Malignancies with a Novel Engineered Small Modular Immunopharmaceutical","volume":"110","author":"Zhao","year":"2007","journal-title":"Blood"},{"key":"ref_32","first-page":"644","article-title":"Significance of CD37 expression in malignant B cells","volume":"22","author":"Wang","year":"2014","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2967\/jnumed.116.173922","article-title":"Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan","volume":"58","author":"Blakkisrud","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00259-018-3964-9","article-title":"Pre-Dosing with Lilotomab Prior to Therapy with 177Lu-Lilotomab Satetraxetan Significantly Increases the Ratio of Tumor to Red Marrow Absorbed Dose in Non-Hodgkin Lymphoma Patients","volume":"45","author":"Stokke","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Repetto-Llamazares, A.H.V., Larsen, R.H., Giusti, A.M., Riccardi, E., Bruland, \u00d8.S., Selbo, P.K., and Dahle, J. (2014). 177Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0103070"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Repetto-Llamazares, A.H.V., Larsen, R.H., Patzke, S., Fleten, K.G., Didierlaurent, D., Pichard, A., Pouget, J.P., and Dahle, J. (2015). Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128816"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/ejh.13139","article-title":"Combination of 177 Lu-Lilotomab with Rituximab Significantly Improves the Therapeutic Outcome in Preclinical Models of Non-Hodgkin\u2019s Lymphoma","volume":"101","author":"Malenge","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Rituximab-Refractory Follicular Non-Hodgkin\u2019s Lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Basirinia, G., Ali, M., Comelli, A., Sperandeo, A., Piana, S., Alongi, P., Longo, C., Di Raimondo, D., Tuttolomondo, A., and Benfante, V. (2024). Theranostic Approaches for Gastric Cancer: An Overview of In Vitro and In Vivo Investigations. Cancers, 16.","DOI":"10.3390\/cancers16193323"},{"key":"ref_40","first-page":"1812","article-title":"The Role of Imaging with 111In-Ibritumomab Tiuxetan in the Ibritumomab Tiuxetan (Zevalin) Regimen: Results from a Zevalin Imaging Registry","volume":"46","author":"Conti","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-Year Follow-up Analysis of Axicabtagene Ciloleucel in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable Response after Tisagenlecleucel in Adults with Relapsed\/Refractory Follicular Lymphoma: ELARA Trial Update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1182\/blood-2022-157691","article-title":"Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed\/Refractory Follicular Lymphoma Who Received \u22652 Prior Therapies: Updated Results from a Pivotal Phase II Study","volume":"140","author":"Bartlett","year":"2022","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and Efficacy of Mosunetuzumab, a Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-Arm, Multicentre, Phase 2 Study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable Responses with Mosunetuzumab in Relapsed\/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I\/II Study","volume":"42","author":"Budde","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/blood-2024-205046","article-title":"Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial","volume":"144","author":"Falchi","year":"2024","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell\u2013Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE NHL-1): A Phase 2 Cohort of a Single-Arm, Multicentre Study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jtct.2023.12.050","article-title":"Deep and Durable Responses with Epcoritamab SC Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Data from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort","volume":"30","author":"Linton","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and Efficacy of Odronextamab in Patients with Relapsed or Refractory Follicular Lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a Human CD20\u00d7CD3 Bispecific Antibody in Patients with CD20-Positive B-Cell Malignancies (ELM-1): Results from the Relapsed or Refractory Non-Hodgkin Lymphoma Cohort in a Single-Arm, Multicentre, Phase 1 Trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3026(24)00345-4","article-title":"Loncastuximab Tesirine with Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-Centre, Single-Arm, Phase 2 Trial","volume":"12","author":"Alderuccio","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2023-174432","article-title":"Preliminary Findings of a Phase Ib\/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e2024012","DOI":"10.4084\/MJHID.2024.012","article-title":"CAR-T Cell Therapy for Follicular Lymphomas","volume":"16","author":"Testa","year":"2024","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_55","unstructured":"(2025, August 18). Study Details|NCT03806179|Study of Safety and Efficacy of Betalutin and Rituximab in Patients with FL|Clini-calTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03806179."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_57","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (2022, January 10). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, Available online: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf."},{"key":"ref_58","unstructured":"European Medicines Agency (EMA) (2025, September 17). ICH E6 Good Clinical Practice\u2014Scientific Guideline|European Medicines Agency (EMA), Available online: https:\/\/www.ema.europa.eu\/en\/ich-e6-good-clinical-practice-scientific-guideline."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/250\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:15:41Z","timestamp":1770095741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ph19020250"],"URL":"https:\/\/doi.org\/10.3390\/ph19020250","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}